Document is current
Any future updates will be listed below
-
Authors
Stepanchick, Emily https://orcid.org/0000-0001-6733-3190
Wilson, Andrew
Sulentic, Analise M. https://orcid.org/0000-0003-2229-3134
Choi, Kwangmin https://orcid.org/0000-0003-4671-962X
Hueneman, Kathleen
Starczynowski, Daniel T. https://orcid.org/0000-0002-5771-7462
Chlon, Timothy M. https://orcid.org/0000-0002-0133-8949
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K01DK121733)
U.S. Department of Defense (W81XWH-22-1-0805)
Edward P. Evans Foundation
American Society of Hematology
Vera and Joseph Dresner Foundation
- License Information
-
More Information
Article History
Received: 20 November 2023
Revised: 5 June 2024
Accepted: 7 June 2024
First Online: 27 June 2024
Competing interests
: DTS serves on the scientific advisory board at Kurome Therapeutics and is a consultant for and/or received funding from Kurome Therapeutics, Captor Therapeutics, Treeline Biosciences, and Tolero Therapeutics. DTS has equity in Kurome Therapeutics. The other authors declare no competing interests.
